Feature | December 09, 2013

ACC Helps Hospitals, Patients Avoid Readmissions

Navigator program brings team approach to meeting patient needs, reducing rehospitalization

December 9, 2013 — With increased penalties in effect for hospitals with excessive readmissions for heart attack and heart failure, the American College of Cardiology (ACC) is launching a program that applies a team approach to keeping patients at home and healthy after discharge.
The ACC created the Patient Navigator Program to support a team of caregivers at selected hospitals to help patients overcome challenges during their hospital stay and in the weeks following discharge when they are at most risk for readmission. Hospitals have been given funding to establish a program that supports a culture of patient-centered care that can potentially be implemented in other hospitals in the future. AstraZeneca is the founding sponsor of the ACC Patient Navigator Program.
“The ACC Patient Navigator Program will serve as a test for innovative, patient-centered solutions to address issues that impact patient health and patient readmissions,” said John Harold, M.D., MACC, and president, ACC. “These hospitals will serve as pioneers in a new approach to heart disease treatment and care that puts emphasis on meeting patients’ ongoing needs and helping patients make a seamless transition from the hospital to the home.”
The Centers for Medicare and Medicaid Services increased penalties beginning Oct. 1 for hospitals with excessive readmission rates for heart attack, heart failure and three other non-cardiac conditions within 30 days of discharge. Hospitals could lose up to 2 percent of related Medicare and Medicaid reimbursements, which is double the prior maximum penalty of 1 percent of Medicare payments. Beginning in 2014, the penalty will increase again to a maximum of 3 percent.
Nearly one in five patients hospitalized with heart attack and one in four patients hospitalized with heart failure are readmitted within 30 days of discharge, often for conditions seemingly unrelated to the original diagnosis. Readmissions can be related to issues like stresses while in the hospital, fragility on discharge, lack of understanding of discharge instructions and inability to carry out discharge instructions.
Out of 132 hospitals initially surveyed about the program, 120 expressed an interest in participating in the first phase of the ACC Patient Navigator Program. Eleven hospitals were chosen for a 2013 program launch, with an additional 24 hospitals slated to join the program by the end of 2015.
Listed below are the first 11 participating hospitals, which were chosen because of their commitment to quality demonstrated by participation in the National Cardiovascular Data Registry and Hospital to Home program:
  • Advocate Sherman Hospital, Elgin, Ill.
  • Christiana Care Health Services, Wilmington, Del.
  • Einstein Medical Center Philadelphia, Philadelphia
  • Indiana University Health Methodist Hospital, Indianapolis
  • MedStar Washington Hospital Center, Washington
  • Providence St. Vincent Medical Center, Portland, Ore.
  • Ronald Reagan UCLA Medical Center, Los Angeles
  • St. Mary’s Hospital, Waterbury, Conn.
  • Trident Health, Charleston, S.C.
  • Vanderbilt Heart and Vascular Institute, Nashville, Tenn.
  • WakeMed Health and Hospital, Raleigh, N.C.
For more information: www.cardiosource.org

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Feature | Cath Lab| November 24, 2015
November 24, 2015 — The U.S.
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
News | Blood Testing| November 18, 2015
Konica Minolta Inc. announced that it has developed the SPFS Immunoassay System, capable of highly sensitive...
MC3 Cardiopulmonary, acquisition, Terumo Cardiovascular Systems, new manufacturing facility, surgical cannula

Image courtesy of MC3 Cardiopulmonary

News | Cardiovascular Surgery| November 10, 2015
MC3 Cardiopulmonary announced it has completed the acquisition and transfer of all assets associated with Terumo...
News | Cath Lab| November 10, 2015
TherOx Inc. announced it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE)...
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Overlay Init